



HAL
open science

Nucleic Acid Immunity and DNA Damage Response: New Friends and Old Foes

Clara Taffoni, Alizée Steer, Johanna Marines, Hanane Chamma, Isabelle Vila,
Nadine Laguette

► **To cite this version:**

Clara Taffoni, Alizée Steer, Johanna Marines, Hanane Chamma, Isabelle Vila, et al.. Nucleic Acid Immunity and DNA Damage Response: New Friends and Old Foes. *Frontiers in Immunology*, 2021, 12, 10.3389/fimmu.2021.660560 . hal-03380383v1

HAL Id: hal-03380383

<https://hal.science/hal-03380383v1>

Submitted on 4 Nov 2021 (v1), last revised 15 Nov 2021 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Nucleic acid immunity and DNA Damage Response: new friends and old foes

Authors:

C. Taffoni^{1,*}, A. Steer¹, J. Marines^{1,2}, H. Chamma¹, I. K. Vila¹ and N. Laguette^{1,*}

Affiliations :

¹ Institut de Génétique Humaine, CNRS, Université de Montpellier, Molecular Basis of Inflammation Laboratory, Montpellier, France,

² Azelead, 377 rue du Pr. Blayac, 34080 Montpellier

* To whom correspondance should be addressed

Abstract

The maintenance of genomic stability in multicellular organisms relies on the DNA damage response (DDR). The DDR encompasses several interconnected pathways that cooperate to ensure the repair of genomic lesions. Besides their repair functions, several DDR proteins have emerged as involved in the onset of inflammatory responses. In particular, several actors of the DDR have been reported to elicit innate immune activation upon detection of cytosolic pathological nucleic acids. Conversely, pattern recognition receptors (PRRs), initially described as dedicated to the detection of cytosolic immune-stimulatory nucleic acids, have been found to regulate DDR. Thus, although initially described as operating in specific subcellular localizations, actors of the DDR and nucleic acid immune sensors may be involved in interconnected pathways, likely influencing the efficiency of one another.

Within this mini review, we discuss evidences for the crosstalk between PRRs and actors of the DDR. For this purpose, we mainly focus on cyclic GMP-AMP (cGAMP) synthetase (cGAS) and Interferon Gamma Inducible Protein 16 (IFI16), as major PRRs involved in the detection of aberrant nucleic acid species, and components of the DNA-dependent protein kinase (DNA-PK) complex, involved in the repair of double strand breaks that were recently described to qualify as potential PRRs. Finally, we discuss how the crosstalk between DDR and nucleic acid-associated interferon responses cooperate for the fine-tuning of innate immune activation, and therefore dictate pathological outcomes. Understanding the molecular determinants of such cooperation will be paramount to the design of future therapeutic approaches.

Keywords: cytosolic nucleic acids, DNA damage responses, inflammation, cGAS-STING, IFI16, DNA-PK, tumorigenesis

1 Introduction

Innate immunity, the first line of host defense, is classically triggered in response to pathogen infection or local lesions to promote infection clearance or wound-healing processes. The activation of innate immune responses vastly relies on pattern-recognition receptors (PRRs) that detect danger associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs). Upon recognition of PAMPs or DAMPs, PRRs trigger signaling cascades leading to the production of soluble mediators, such as type I Interferons, cytokines and chemokines. Pathogen-derived nucleic acids constitute major PAMPs that are detected by a vast array of PRRs that operate in specific subcellular localizations. In recent years, self-nucleic acids, originating from replication stress [1], DNA or mitochondrial damage [2], and endogenous retroelement activation [3], have been identified as substrates for cytosolic PRRs, and are thus considered as DAMPs. Because nucleic acids are abundant in cells, the activity of PRRs engaged in their detection is regulated and compartmentalized [4]. PRRs dedicated to nucleic acid detection also present substrate specificity, with subclasses dedicated to the detection of particular moieties [5].

A plethora of cytosolic nucleic acid sensors have been described to participate in triggering interferon responses. Such receptors notably include the ubiquitous DNA-dependent activator of interferon regulatory factors (DAI) [6], AIM2 [7; 8], Interferon gamma-inducible protein 16 (IFI16) [9], melanoma differentiation factor 5 (MDA5) [10] and retinoic acid-inducible gene (RIG-I) [10]. An extensive description of the mechanism of action of the above mentioned PRRs can be found in [11]. Amongst pathways involved in cytosolic nucleic acid detection, the Stimulator of Interferon genes (STING) protein constitutes a central signaling hub [12; 13]. Initial reports indicated that STING activation requires detection of cytosolic nucleic acid species such as double strand (dsDNA), single strand (ssDNA), or RNA:DNA species [14;15;16] by the cyclic GMP-AMP (cGAMP) synthase (cGAS) PRR [14]. The main signature of activation of this signaling pathway is the production of type I Interferons that in turn promote the production of interferon-stimulated genes (ISGs). This signaling pathway has attracted tremendous biomedical interest in recent years, notably with observation that agonists of STING can boost antitumoral immunity [17].

However, there is emerging evidence for an intricate signaling network beyond the cGAS-STING cascade, which cannot be overlooked in therapeutic strategies aiming to boost STING activation. Of particular importance is the fact that cGAS and STING have been both described as involved in genotoxic stress response and to participate to the maintenance of genomic integrity. Furthermore, the DNA-PK complex, which is best known for its function in non-homologous end-joining (NHEJ)-mediated repair of dsDNA breaks (DSB), has been shown to serve as an alternative route to stimulate type I Interferon production [18] [19; 20; 21]. In parallel, the Interferon Gamma Inducible Protein 16 (IFI16) was also reported to detect, in concert or not with cGAS, DNA damage-derived nucleic acid species [9; 22; 23], and to cooperate with DDR proteins to promote STING-dependent immune responses following genotoxic stress [22]. Furthermore, cGAS and STING have been shown to control genomic stability [24; 25]. Thus, the current literature highlights tight connections between DNA repair processes and nucleic acid-associated inflammatory responses. Indeed, proteins involved in the recognition of abnormal DNA, regardless of their origin, appear to possess common roles in the initiation of inflammatory responses and surveillance of genomic integrity.

In this mini review, we discuss this interconnection between DNA repair mechanisms and nucleic acid immunity, by focusing on the cGAS and IFI16 receptors and the way in which they control STING activation. While several DNA repair proteins have been involved in the fine tuning of inflammatory responses [22; 26], here we focus on the DNA-PK complex, responsible for NHEJ, for which a role in controlling nucleic acid-dependent inflammatory responses has been reported [26]. We discuss how dissecting these signaling networks will deepen our understanding of Interferon responses, which is likely crucial to the design of therapeutic responses to pathological inflammation.

2 Cytosolic nucleic acid detection: STING as a central signaling hub

2.1 The cGAS-STING pathway

The production of type I Interferons, in the presence of cytosolic nucleic acid species, was initially described to rely mostly on cGAS [14]. Indeed, cGAS detects dsDNA, ssDNA, or RNA:DNA species [14; 15; 16] in the cytosol and catalyzes the synthesis of cGAMP (Figure 1A). Although the binding of cGAS to nucleic acid species is sequence-independent, cGAS activation is increased by longer dsDNA fragments [27; 28], suggesting that portions of chromosomes, such as those arising in the micronucleation process, would serve as potent substrates for cGAS. cGAMP interacts with the endoplasmic reticulum (ER)-resident STING adaptor protein [29; 30], promoting conformational changes [29; 31], oligomerization [32] and translocation to perinuclear compartments, including the Golgi apparatus [12; 33]. Subsequent recruitment of the TANK-binding kinase 1 (TBK1) [34], together with transcription factors, such as Nuclear Factor Kappa B (NF- κ B) and Interferon Response Factor 3 (IRF3), ultimately leads to the transcription of a repertoire of inflammatory cytokines characterized by a type I Interferon signature [12; 35] (Figure 1A). NF- κ B activation may also be promoted by IKK ϵ , in addition to TBK1, in macrophages. The cGAS-STING cascade is triggered upon cytosolic exposure of foreign nucleic acid species, following pathogen infection, but also by nucleus- and mitochondria-derived self-nucleic acids that leak into the cytosol following various types of stress [2; 36; 37; 38; 39] and through DNA recombination processes [40].

Yet, the cGAS-cGAMP-STING signaling axis has recently emerged as far more complex than initially anticipated. First, multiple post-translational modifications influence signaling output [41; 42; 43]. Second, STING can be directly activated by bacterial cyclic di-nucleotides [44; 45], while its activation is skewed by alternative di-nucleotides [16] or other metabolites [46]. Third, co-sensors, co-factors and alternative upstream STING activators have been described, that can operate in cell type-specific manners [23; 47; 48; 49]. Finally, in addition to the cell-autonomous capacity of cGAMP to activate STING-dependent Interferon responses, cGAS-STING signaling may also be amplified through transfer of cGAMP to neighboring cells through gap junctions [50; 51; 52], direct secretion [53] or in vesicles [54].

Below, we focus on IFI16 and DNA-PK as alternative sensors involved in the regulation of STING-dependent interferon responses.

2.2 IFI16: an alternative nucleic acid sensor

IFI16 is a predominantly nuclear protein that has been described as involved in the induction of innate immune responses upon infection by viruses, including Herpes simplex virus [9], Epstein-Barr virus [55], and Kaposi's sarcoma-associated Herpes virus [56]. Indeed, in this context, IFI16 promotes IRF3- and NF- κ B-dependent Interferon production via STING

[9](Figure 1, B). Similar to cGAS, IFI16 is capable of detecting self and non-self DNA, and displays a preference for long non-self dsDNA [57]. Unlike cGAS, IFI16 operates mostly in a cell-type-dependent manner [23; 49]. The interplay between cGAS and IFI16 has been explored, revealing cooperation between IFI16 and cGAS upon infection (Figure 1B, left). This cooperation relies on cell-type specific molecular mechanisms. Indeed, in both keratinocytes and macrophages, IFI16 cooperates with cGAS for STING activation upon infection [23; 49]. However, in macrophages, IFI16 enhances cGAS-dependent cGAMP production [49], while in keratinocytes, IFI16 does not influence cGAMP production, but rather directly activates STING [23]. Additionally, IFI16 has been shown to promote inflammasome activation in the nucleus, leading to production of Interleukin-1 β (IL-1 β), IL-18, and IL-33 cytokines [55; 58].

In contrast, following genotoxic stress, IFI16 triggers cGAS-independent STING activation (Figure 1B, right). Indeed, upon etoposide-induced DNA lesions, IFI16, together with DDR proteins, activates STING, promoting the assembly of a non-canonical STING signalosome [22]. Within this complex IFI16 promotes TNF Receptor Associated Factor 6 (TRAF6)-dependent STING ubiquitination and activation ultimately leading to the predominant activation of the transcription factor NF κ B, rather than IRF3 [22]. Therefore, this signaling cascade results in the expression of a repertoire of cytokines that differs from that triggered upon cGAS-mediated detection of dsDNA, including a specific IL-6 and CCL20 signature [22]. Yet, most of the described mechanisms were inferred from the study of keratinocytes or myeloid cell lines, leaving uncertainties concerning the activation of IFI16 in cancer cells.




Figure 1: Intertwined cytosolic nucleic acid pathways involved in interferon and pro-inflammatory cytokine production in human cells. A: The cGAS sensor activates STING via the production of the cGAMP second messenger. B: From left to right: the IFI16 sensor mediates inflammation through multiple routes: upon viral infection it activates STING in a cell type-specific manner, either enhancing cGAS-dependent cGAMP production in macrophages or by directly activating STING in keratinocytes; upon genotoxic stress it mediates cGAS-independent, but TRAF6-dependent STING activation.. C: the DNA-PK DNA repair complex was shown to play a role in inducing type I Interferon production upon cytosolic dsDNA detection. However, multiple downstream mechanisms have been proposed, that require STING activation or not, ultimately leading to the phosphorylation of transcription factors responsible for type I Interferon production. The catalytic subunit of the DNA-PK complex (DNA-PKcs) can also suppress cGAS enzymatic activity, by promoting its phosphorylation. IFNs: Interferons.

2.3 DNA-PK: bridging DNA repair and nucleic acid immunity

The DNA-PK complex has been reported to play a role in controlling nucleic acid-dependent inflammation. The DNA-PK complex is a key holoenzyme, composed of KU70XRCC6, KU80XRCC5 and the DNA-dependent protein kinase catalytic subunit DNA-PKcsPRKDC, central to the repair of DSBs by NHEJ. NHEJ is involved in the repair of approximately 80% of DSBs and can operate regardless of the cell cycle phase. It promotes resection of DNA ends without requirement for an intact template [59]. KU70/KU80 heterodimers interact directly with damaged DNA ends and are responsible for the recruitment of DNA-PKcs to these lesions. DNA-PKcs bears a kinase activity and promotes both DNA-PKcs autophosphorylation and the phosphorylating-activation of effector proteins required for the NHEJ process. For a complete recent view of NHEJ refer to [60].

Besides its canonical role in NHEJ while it recognizes self dsDNA, there are several reports for a central role of DNA-PK in the detection of exogenous DNA species and interference with viral life cycles [61]. Subunits of the complex have been independently reported to trigger or skew inflammatory responses towards either type I or type III Interferon production in response to non-self dsDNA. Indeed, KU70 triggers DNA-dependent type III Interferon responses through activation of Interferon Regulatory Factor 1 and 7 (IRF1 and IRF7) [19; 62], independently of DNA-PKcs [19].

In contrast, recent reports indicate that the catalytic activity of DNA-PKcs is also crucial for antiviral responses. Indeed, DNA-PKcs promotes IRF3 phosphorylation following infection by DNA and RNA viruses [18; 63]. Interaction between DNA-PKcs and the progenome of the Human Immunodeficiency Virus (HIV) retrovirus has also been shown, although the link to inflammation is unexplored [64]. Interestingly, some DNA viruses have evolved proteins that counteract DNA-PKcs-dependent detection [20] while others hijack NHEJ to the benefit of their replication [65], highlighting the tight interplay between viral life cycles and DDR [66]. Yet, there is as of today, limited knowledge concerning the ways in which DNA-PK-dependent inflammatory responses, IFI16- and cGAS-dependent STING activation are orchestrated.

Indeed, whether DNA-PK requires STING for production of Interferons remains debated [18; 20; 67]. It was reported that DNA-PKcs is recruited to dsDNA in the cytoplasm of both human and murine cells through KU80, triggering IRF3-dependent inflammatory responses [18]. However, while some reports indicate that the catalytic activity of DNA-PKcs is responsible for direct activating phosphorylation of IRF3 [63], others indicate that the measured Interferon production can occur independently of the catalytic activity of DNA-PKcs [18]. In this latter scenario, questions remain open concerning what would trigger IRF3 activation. It has also been proposed that DNA-PKcs would act upstream of TBK1 and IRF3 [18] and that KU70 can form a complex with STING prior to [18], or upon [19] DNA transfection. This notion was comforted by Morchikh et al, in 2017, showing that DNA-PK subunits (DNA-PKcs, KU70 and KU80) are associated with a ribonuclear complex that is remodeled by foreign DNA, leading to enhanced recruitment of STING, activated DNA-PKcs, and IRF3 [67]. However, a recent study has shown that DNA-PKcs can also operate independently of STING [20] and that DNA-PKcs can phosphorylate cGAS and suppresses its enzymatic activity [21]. Considering the tight link between DNA-PK activation and cell cycle progression [68], and in view of the recent reports linking cGAS activation and cell cycle stage [69], the crosstalk between DNA-PK and cGAS-STING activation would certainly benefit from integrating the temporality of events to

the study. In agreement, it was previously reported that inhibition of NHEJ components reduces Interferon signalling, in a cell cycle progression-dependent manner [70].

Adding a layer of complexity, DNA-PKcs immune signaling appears to be species-specific. Indeed DNA-PKcs can activate innate immune responses independently of STING in human cells, but not in murine cells [20]. This is consistent with previous reports that in mouse cell lines, where the immune response is largely dependent on STING, DNA-PKcs would signal through STING [18]. Furthermore, the current state-of-the-art does not allow determining whether the role of DNA-PK in inducing type I Interferon responses may be subjected to cell type-specific regulatory mechanisms, as was reported for IFI16. In this respect, how IFI16 activation is regulated in contexts where DNA-PKcs activates inflammatory responses remains to be elucidated.

3 Regulation of the DNA damage response by innate immune sensing pathways

3.1 cGAS suppresses DNA damage responses

The cGAS protein was initially identified as the main receptor for cytosolic nucleic acid moieties that promote type I Interferon responses [14]. However, it was recently demonstrated that an abundant pool of cGAS is tethered to the chromatin, in absence of inflammatory stimulus [71; 72; 73]. Active export of cGAS through the Chromosomal Maintenance 1 (CRM1) exportin was recently demonstrated, suggesting that shuttling of cGAS to the cytosol may be a prerequisite for its activation [74]. However, the molecular mechanisms triggering cGAS nuclear export and whether cGAS may also be activated in the nucleus, remains to be clarified. There is evidence for a role of cGAS in the inhibition of Homologous Recombination (HR)-mediated repair of DSB. Contrary to NHEJ, that operates in a cell cycle stage-independent manner, HR requires the presence of the sister chromatid for accurate repair of DNA lesions [75] and therefore operates mostly during the G2/M phase of the cell cycle. HR is a complex, multistep process that can be completed through several interconnected pathways, for which a complete overview can be found in [76]. Two mechanisms have been proposed for cGAS-dependent HR inhibition (Figure 2, left). On one hand, Liu et al. showed that DNA damage triggers cGAS nuclear translocation and interaction with activated DNA damage-dependent Poly [ADP-ribose] polymerase 1 (PARP1), which is a first responder in DNA damage detection. Interaction of cGAS with PARP1 prevents the recruitment of proteins required to proceed through HR process and does not require the cGAS DNA-binding domain [77]. However, since the majority of cellular cGAS is nuclear [71; 72; 73], one may question why the cytosolic rather than the chromatinian pool of cGAS would be mobilized. This may be linked to the high affinity of cGAS for the acidic patch of histones that renders chromatinian cGAS not easily displaceable [72]. On the other hand, Jiang et al. observed that the DNA-binding domain of chromatin-bound cGAS is crucial for cGAS oligomerization on DNA, hindering the formation of displacement loops, which are required for HR to proceed [78]. Consequently, upon irradiation, cells expressing cGAS present increased accumulation of DSBs as compared to cells that do not express cGAS. Intriguingly, this function is reportedly independent of cGAS-mediated innate immune sensing [78].

3.2 STING as a promoter of DNA damage response

STING, the major downstream partner of cGAS, has been proposed to promote DDR and to enable cell survival, in an inflammation-independent manner (Figure 2, right). An important

part of the regulation of STING activation is linked to its subcellular localization, with inactive STING resting in the ER and activation promoting its relocation to the Golgi apparatus. Interestingly, in certain contexts, such as following chemotherapy regimens, STING colocalizes with γ H2AX-positive DNA damage foci, at the inner nuclear membrane [79]. In addition, cells knocked-down for STING present accumulation of DNA damage as compared to WT cells [79]. No clear molecular mechanism has been proposed yet, although STING has been demonstrated to interact with NHEJ proteins, including DNA-PKcs, KU70 and KU80 [18; 19; 67; 79], suggesting that it may participate directly in the regulation of NHEJ. Moreover, STING overexpression leads to increased binding of DNA-PK to chromatin, suggesting that STING may cooperate with DNA-PK to control NHEJ-mediated DNA repair [79]. However, the contribution of STING to NHEJ efficiency was not addressed, calling for further investigation.

Altogether, the subcellular localization of PRRs is central to the regulation of their activity, and determines whether they mediate repair- or immune-related functions. This is similar to what is witnessed for components of DNA-PK that are engaged in DNA repair or innate immune activation, depending on their subcellular localization and interactors. How these pathways cooperate or antagonize each other in given pathological situations, and in particular in the case of genotoxic stress that induces both repair and immune activation, remains to be elucidated.




Figure 2: Pattern Recognition Receptors are involved in regulating DNA damage repair processes.

Left, The cGAS sensor can inhibit DNA Damage Responses (DDR) via two distinct mechanisms in human cells: 1) cGAS inhibits the Homologous Recombination (HR) pathway by preventing displacement loop (D-loop) formation. 2) cGAS-PARP1 interaction impedes the formation of a PARP1-based complex required for HR-mediated DNA repair. Right, STING promotes DDR in human cells through a yet to be elucidated molecular mechanism, but may rely on the control of components of the Non-Homologous End Joining DNA repair pathway, such as the DNA-PK complex. Dashed arrow between STING and DNA-PK represents the reported interaction between the two proteins [19; 67; 79]. Whether this interaction is related to STING-associated DDR control is unknown.

4 Cooperation between DDR and innate immunity in tumorigenesis

The interplay between innate immune activation and DNA repair pathways is likely to be central to our understanding of several human pathologies. For instance, several cancer susceptibility syndromes, such as Fanconi Anemia, that present with inheritable deficiencies in DNA repair pathways also display hematological disorders, such as bone marrow failure or auto-immunity, together with elevated type I Interferon levels. Mutations in DNA repair proteins are also found in diseases primarily defined as auto-inflammatory as described thoroughly in Ragu et al [26]. Indeed, deficient DDR frequently leads to pathologies, such as Ataxia-Telangiectasia, Werner Syndrome and Bloom Syndrome, in which inflammation plays a great part [80; 81; 82]. Likewise, chronic inflammation plays an important role in all stages of sporadic cancer, from the onset of neoplastic lesions to metastatic dissemination [83].

Although STING targeting immunotherapies have seen a huge biomedical interest in recent years, the study of the impact of STING activation on tumorigenesis has revealed an extremely complex relationship with tumor fate. In many cases STING activation has been shown to promote tumor clearance. Nucleic acid substrates for cGAS in tumors can result from the release of chromatin fragments in the cytosol of tumor cells [84], leading to cGAS-STING activation and cell cycle arrest [84; 85; 86]. In addition, released self-DNA, from dying tumor cells in the tumor microenvironment can be engulfed by intra-tumoral antigen-presenting cells (APCs), such as dendritic cells and macrophages and likely activates the cGAS-STING pathway [87], through mechanisms that are still under debate [88]. The resulting cGAS-STING pathway activation promotes maturation and cross-presentation [89], ultimately leading to the recruitment and the infiltration of cytotoxic CD8(+) T cells at the tumor site [90; 91]. Moreover, tumor-derived cGAMP promotes immune cells infiltration [51]. Importantly, the cGAS-STING pathway was shown to potentiate the response to radiotherapy and chemotherapy [87; 92] and to synergize with checkpoint inhibitors [93; 94]. Thus, activating the cGAS-STING axis in combination with chemotherapy and/or immunotherapy appears as a valuable therapeutic strategy.

However, there is evidence that cGAS-STING-dependent inflammation can fuel tumorigenesis [95], promote tolerogenic responses, impair the establishment of long-term immunity [96] and lead to chemoresistance [97; 98]. Indeed, transfer of cGAMP from metastatic cells to astrocytes through gap junctions was also shown to support metastatic dissemination and chemoresistance [99]. Finally, accumulation of micronuclei in the cytoplasm of cancer cells following ionizing radiation promotes STING-dependent inflammation [39; 70] and metastasis [100]. It has been proposed that tumor grade and origin may account for these differential outcomes following cGAS-STING stimulation, calling for stratification strategies to identify patients that would benefit from cGAS-STING targeting immunotherapies.

Moreover, present therapeutic regimens include the use of DDR inhibitors in combination or not with radiotherapy [93; 101; 102; 103]. Indeed, this approach induces accumulation of inflammatory cytosolic nucleic acids, leading to cGAS-STING pathway activation [94; 104] and promoting T cell infiltration and thus tumor regression [94; 101]. Significant tumor regression has also been observed using DNA-PKcs inhibitors in combination with chemotherapy or radiotherapy [68], however the role of inflammation in this process is at present unexplored. Considering the emerging role of DDR proteins in innate immune responses, it is tempting to speculate that upon genotoxic stress, DDR proteins may directly

fuel cancer-related inflammatory responses. In addition, numerous tumors down regulate the expression of cGAS and/or STING [105; 106]. In these contexts, it would be important to examine if DDR proteins may take over the production of inflammatory cytokines.

Furthermore, STING activation has been shown to promote two distinct transcriptional programs. On one hand, activation of genes under the control IRF-3, leads mostly to the production of type I Interferons that are generally accepted as acting anti-cancer agents [107], while NF- κ B activation promotes the production of cytokines that are mostly considered pro-tumorigenic, such as IL-6 [108; 109]. Indeed, increased plasma levels of IL-6 generally negatively correlate with patient survival in many cancers [109]. It would be crucial to determine whether the differential outcomes of STING activation observed in studies describing STING activation as pro-tumorigenic would result from IL-6 secretion. Ultimately, it would be crucial to determine, in those contexts where alternative receptors to cGAS would potentiate STING-dependent signaling, whether they would lead to skewing of the response towards IL-6 production and promote pathological outcomes.

Reciprocally, regulation of DDR by PRRs is likely to affect tumorigenesis. HR inhibition by chromatin-bound cGAS accelerates genome destabilization and micronuclei generation, leading to cell death both in vitro and in vivo [78]. Thus, cGAS may thereby restrict the propagation of cancer cells. To the contrary, alterations of cGAS shuttling towards the cytosol correlate with poor patient prognosis [77]. This suggests that nuclear translocation of cGAS and subsequent HR inhibition may promote tumorigenesis [77], although this may also be linked to defective cGAS-dependent Interferon responses. Furthermore, IFI16 has also been reported to present nuclear functions [56; 110], including a role in regulation of cell cycle arrest [110; 111]. Supporting an association between IFI16 and tumorigenesis, IFI16 levels are frequently decreased in breast cancer cell lines [112]. Yet, there is as of today no clear implication of IFI16-dependent cytokine production in tumorigenesis. This leaves open the possibility that IFI16 may be mobilized in tumors where cGAS expression is downregulated. Thus, deciphering the molecular cues leading to the mobilization of the different pools of cGAS, or alternative receptors such as IFI16, to detect immune-stimulatory DNA - and the impact of the different PRRs in DNA damage responses - is likely primordial to the understanding of how nucleic acid detection dictates tumor fate.

5 Discussion

Accumulation of cytosolic nucleic acids, including ssDNA, dsDNA and RNA:DNA hybrids, has been documented in several etiologically distinct human pathologies that present with pathological type I Interferon responses [113]. Importantly, the range of symptoms experienced by patients is broad, and as of today not fully understood.

Much attention was brought to the cGAS-STING axis, notably because it was shown that cGAS is non-dispensable for STING activation in vivo. Indeed, in cells, including dendritic cells, macrophages or fibroblasts, from cGAS-deficient mice, nucleic acid-dependent STING activation was abolished [114]. Yet, recent research has underlined the existence of species-specificities in innate immune detection of nucleic acids [115]. Thus, although the cGAS-STING cascade represents a crucial cytosolic dsDNA detection route, a more complex picture is currently emerging. In addition to the many direct regulators of the cGAS-STING pathway,

alternative receptors such as IFI16 and DNA-PK, may mediate stimulus-specific Interferon responses. Therefore, previously overlooked nucleic acid sensors should be re-examined [116]. In particular, the recently uncovered cooperation between DDR and nucleic acid immunity can be expected to contribute to the health alterations witnessed in patients presenting with chronic inflammation while feeding cancer susceptibility directly.

Importantly, in inflammatory pathologies, it is generally considered a risky approach to directly act on pathways responsible for Interferon production [117]. This is intrinsically linked to the duality of the impacts of Interferons, that can either be beneficial or promote cytopathic effects, depending on multiple parameters that are as of today poorly understood. Several chronic inflammatory pathologies, presenting with type I Interferon overproduction, such as type I Interferonopathies, or Aicardi-Goutières Syndromes are treated with inhibitors of the Janus kinase 1, 2 and 3 [118]. This treatment, rather than halting Interferon production, prevents the induction of ISGs following the interaction of Interferons with its cognate receptor. However, such disruption of immune pathways comes at the expense of increased risk of infection [118]. Identification of pathways responsible for activation of pathological immune responses and the design of specific targeting strategies may be valuable in these pathologies. Addressing whether DDR proteins are involved in the inflammatory signature present in these diseases is thus important.

Altogether, the current state-of-the-art supports that STING is an attractive target for the treatment of autoimmune, inflammatory diseases and cancer [17; 119]. However, emerging regulators, cell type specific or stimulus specific responses, together with alternative functions of STING and its activators, indicate that our understanding of nucleic acid immunity is still in its infancy. Our view of how immune-stimulatory DNAs are detected is likely to grow in complexity, notably with the addition of DNA repair proteins to the list of PRRs. Therefore, the regulatory mechanisms and crosstalk between engaged pathways will surely remain an area of intense research in coming years.

Figure 2: Pattern Recognition Receptors are involved in regulating DNA damage repair processes. Left, The cGAS sensor can inhibit DNA Damage Responses (DDR) via two distinct mechanisms in human cells: 1) cGAS inhibits the Homologous Recombination (HR) pathway by preventing displacement loop (D-loop) formation. 2) cGAS-PARP1 interaction impedes the formation of a PARP1-based complex required for HR-mediated DNA repair. Right, STING promotes DDR in human cells through a yet to be elucidated molecular mechanism, but may rely on the control of components of the Non-Homologous End Joining DNA repair pathway, such as the DNA-PK complex. Dashed arrow between STING and DNA-PK represents the reported interaction between the two proteins [19; 67; 79]. Whether this interaction is related to STING-associated DDR control is unknown.

5.1.1 Permission to reuse and Copyright

Figures, tables, and images will be published under a Creative Commons CC-BY licence and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.

6 Conflict of Interest

The authors declare no competing interest.

7 Author Contributions

CT, AS, IKV, HC, JM and NL drafted and edited the manuscript. Visualization: IKV.

8 Funding

Work in NL's laboratory is supported by grants from the European Research Council (ERC-Stg CrIC: 637763, ERC-PoC DIM-CrIC: 893772), "LA LIGUE pour la recherche contre le cancer" and the "Agence Nationale de Recherche sur le SIDA et les Hépatites virales" (ANRS). CT was supported by Merck Sharp and Dohme Avenir (MSD-Avenir – GnoSTic) program, followed by an ANRS fellowship (ECTZ119088). JM was supported by a "Conventions Industrielles de Formation par la Recherche" (CIFRE) fellowship from the "Agence Nationale de Recherche Technologie" (ANRT). AS is supported by the ERC-PoC DIM-CrIC (893772). IKV was supported by the European Research Council (637763) followed by the Prix Roger PROPICE pour la recherche sur le cancer du pancréas » of the Fondation pour la Recherche Médicale (FRM, ARF20170938586). HC is supported by a PhD Fellowship from "La Ligue contre le cancer". We acknowledge the SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553 for support.

9 Acknowledgments

We thank C. Langevin for critical reading of the manuscript.

10 Reference

- [1] F. Coquel, M.J. Silva, H. Techer, K. Zadorozhny, S. Sharma, J. Nieminuszczy, C. Mettling, E. Dardillac, A. Barthe, A.L. Schmitz, A. Promonet, A. Cribier, A. Sarrazin, W. Niedzwiedz, B. Lopez, V. Costanzo, L. Krejci, A. Chabes, M. Benkirane, Y.L. Lin, and P. Pasero, SAMHD1 acts at stalled replication forks to prevent interferon induction. *Nature* 557 (2018) 57-61.
- [2] A. Rongvaux, R. Jackson, C.C. Harman, T. Li, A.P. West, M.R. de Zoete, Y. Wu, B. Yordy, S.A. Lakhani, C.Y. Kuan, T. Taniguchi, G.S. Shadel, Z.J. Chen, A. Iwasaki, and R.A. Flavell, Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. *Cell* 159 (2014) 1563-77.
- [3] C. Bregnard, J. Guerra, S. Dejardin, F. Passalacqua, M. Benkirane, and N. Laguette, Upregulated LINE-1 Activity in the Fanconi Anemia Cancer Susceptibility Syndrome Leads to Spontaneous Pro-inflammatory Cytokine Production. *EBioMedicine* 8 (2016) 184-194.
- [4] G.M. Barton, and J.C. Kagan, A cell biological view of Toll-like receptor function: regulation through compartmentalization. *Nat Rev Immunol* 9 (2009) 535-42.
- [5] W. Chuenchor, T. Jin, G. Ravilious, and T.S. Xiao, Structures of pattern recognition receptors reveal molecular mechanisms of autoinhibition, ligand recognition and oligomerization. *Curr Opin Immunol* 26 (2014) 14-20.
- [6] A. Takaoka, Z. Wang, M.K. Choi, H. Yanai, H. Negishi, T. Ban, Y. Lu, M. Miyagishi, T. Kodama, K. Honda, Y. Ohba, and T. Taniguchi, DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature* 448 (2007) 501-5.

- [7] V. Hornung, A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D.R. Caffrey, E. Latz, and K.A. Fitzgerald, AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* 458 (2009) 514-8.
- [8] T. Fernandes-Alnemri, J.W. Yu, P. Datta, J. Wu, and E.S. Alnemri, AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature* 458 (2009) 509-13.
- [9] L. Unterholzner, S.E. Keating, M. Baran, K.A. Horan, S.B. Jensen, S. Sharma, C.M. Sirois, T. Jin, E. Latz, T.S. Xiao, K.A. Fitzgerald, S.R. Paludan, and A.G. Bowie, IFI16 is an innate immune sensor for intracellular DNA. *Nat Immunol* 11 (2010) 997-1004.
- [10] X. Jiang, L.N. Kinch, C.A. Brautigam, X. Chen, F. Du, N.V. Grishin, and Z.J. Chen, Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. *Immunity* 36 (2012) 959-73.
- [11] L. Unterholzner, The interferon response to intracellular DNA: why so many receptors? *Immunobiology* 218 (2013) 1312-21.
- [12] H. Ishikawa, Z. Ma, and G.N. Barber, STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* 461 (2009) 788-92.
- [13] G.N. Barber, STING: infection, inflammation and cancer. *Nat Rev Immunol* 15 (2015) 760-70.
- [14] L. Sun, J. Wu, F. Du, X. Chen, and Z.J. Chen, Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* 339 (2013) 786-91.
- [15] P.J. Kranzusch, A.S. Lee, J.M. Berger, and J.A. Doudna, Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. *Cell Rep* 3 (2013) 1362-8.
- [16] J. Guerra, A.L. Valadao, D. Vlachakis, K. Polak, I.K. Vila, C. Taffoni, T. Prabakaran, A.S. Marriott, R. Kaczmarek, A. Houel, B. Auzemery, S. Dejardin, P. Boudinot, B. Nawrot, N.J. Jones, S.R. Paludan, S. Kossida, C. Langevin, and N. Laguette, Lysyl-tRNA synthetase produces diadenosine tetraphosphate to curb STING-dependent inflammation. *Sci Adv* 6 (2020) eaax3333.
- [17] A. Li, M. Yi, S. Qin, Y. Song, Q. Chu, and K. Wu, Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. *J Hematol Oncol* 12 (2019) 35.
- [18] B.J. Ferguson, D.S. Mansur, N.E. Peters, H. Ren, and G.L. Smith, DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. *Elife* 1 (2012) e00047.
- [19] H. Sui, M. Zhou, H. Imamichi, X. Jiao, B.T. Sherman, H.C. Lane, and T. Imamichi, STING is an essential mediator of the Ku70-mediated production of IFN-lambda1 in response to exogenous DNA. *Sci Signal* 10 (2017).
- [20] K. Burleigh, J.H. Maltbaek, S. Cambier, R. Green, M. Gale, Jr., R.C. James, and D.B. Stetson, Human DNA-PK activates a STING-independent DNA sensing pathway. *Sci Immunol* 5 (2020).

- [21] X. Sun, T. Liu, J. Zhao, H. Xia, J. Xie, Y. Guo, L. Zhong, M. Li, Q. Yang, C. Peng, I. Rouvet, A. Belot, H.B. Shu, P. Feng, and J. Zhang, DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity. *Nat Commun* 11 (2020) 6182.
- [22] G. Dunphy, S.M. Flannery, J.F. Almine, D.J. Connolly, C. Paulus, K.L. Jonsson, M.R. Jakobsen, M.M. Nevels, A.G. Bowie, and L. Unterholzner, Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-kappaB Signaling after Nuclear DNA Damage. *Mol Cell* 71 (2018) 745-760 e5.
- [23] J.F. Almine, C.A. O'Hare, G. Dunphy, I.R. Haga, R.J. Naik, A. Atrih, D.J. Connolly, J. Taylor, I.R. Kelsall, A.G. Bowie, P.M. Beard, and L. Unterholzner, IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes. *Nat Commun* 8 (2017) 14392.
- [24] A. Basit, M.G. Cho, E.Y. Kim, D. Kwon, S.J. Kang, and J.H. Lee, The cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. *Exp Mol Med* 52 (2020) 643-657.
- [25] H. Chen, H. Chen, J. Zhang, Y. Wang, A. Simoneau, H. Yang, A.S. Levine, L. Zou, Z. Chen, and L. Lan, cGAS suppresses genomic instability as a decelerator of replication forks. *Sci Adv* 6 (2020).
- [26] S. Ragu, G. Matos-Rodrigues, and B.S. Lopez, Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response. *Genes (Basel)* 11 (2020).
- [27] S. Luecke, A. Holleufer, M.H. Christensen, K.L. Jonsson, G.A. Boni, L.K. Sorensen, M. Johannsen, M.R. Jakobsen, R. Hartmann, and S.R. Paludan, cGAS is activated by DNA in a length-dependent manner. *EMBO Rep* 18 (2017) 1707-1715.
- [28] L. Andreeva, B. Hiller, D. Kostrewa, C. Lassig, C.C. de Oliveira Mann, D. Jan Drexler, A. Maiser, M. Gaidt, H. Leonhardt, V. Hornung, and K.P. Hopfner, cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders. *Nature* 549 (2017) 394-398.
- [29] X. Zhang, H. Shi, J. Wu, X. Zhang, L. Sun, C. Chen, and Z.J. Chen, Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. *Mol Cell* 51 (2013) 226-35.
- [30] J. Wu, L. Sun, X. Chen, F. Du, H. Shi, C. Chen, and Z.J. Chen, Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. *Science* 339 (2013) 826-30.
- [31] P. Gao, M. Ascano, T. Zillinger, W. Wang, P. Dai, A.A. Serganov, B.L. Gaffney, S. Shuman, R.A. Jones, L. Deng, G. Hartmann, W. Barchet, T. Tuschl, and D.J. Patel, Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. *Cell* 154 (2013) 748-62.
- [32] G. Shang, C. Zhang, Z.J. Chen, X.C. Bai, and X. Zhang, Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP. *Nature* 567 (2019) 389-393.
- [33] T. Saitoh, N. Fujita, T. Hayashi, K. Takahara, T. Satoh, H. Lee, K. Matsunaga, S. Kageyama, H. Omori, T. Noda, N. Yamamoto, T. Kawai, K. Ishii, O. Takeuchi, T. Yoshimori,

and S. Akira, Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad Sci U S A* 106 (2009) 20842-6.

[34] Y. Tanaka, and Z.J. Chen, STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. *Sci Signal* 5 (2012) ra20.

[35] T. Abe, and G.N. Barber, Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. *J Virol* 88 (2014) 5328-41.

[36] X. Tan, L. Sun, J. Chen, and Z.J. Chen, Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids. *Annu Rev Microbiol* 72 (2018) 447-478.

[37] J. Klarquist, C.M. Hennies, M.A. Lehn, R.A. Reboulet, S. Feau, and E.M. Janssen, STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. *J Immunol* 193 (2014) 6124-34.

[38] D. Gao, T. Li, X.D. Li, X. Chen, Q.Z. Li, M. Wight-Carter, and Z.J. Chen, Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. *Proc Natl Acad Sci U S A* 112 (2015) E5699-705.

[39] K.J. Mackenzie, P. Carroll, C.A. Martin, O. Murina, A. Fluteau, D.J. Simpson, N. Olova, H. Sutcliffe, J.K. Rainger, A. Leitch, R.T. Osborn, A.P. Wheeler, M. Nowotny, N. Gilbert, T. Chandra, M.A.M. Reijns, and A.P. Jackson, cGAS surveillance of micronuclei links genome instability to innate immunity. *Nature* 548 (2017) 461-465.

[40] G. Pepin, J. Ferrand, K. Honing, W.S. Jayasekara, J.E. Cain, M.A. Behlke, D.J. Gough, G.W. BR, V. Hornung, and M.P. Gantier, Cre-dependent DNA recombination activates a STING-dependent innate immune response. *Nucleic Acids Res* 44 (2016) 5356-64.

[41] K.P. Hopfner, and V. Hornung, Molecular mechanisms and cellular functions of cGAS-STING signalling. *Nat Rev Mol Cell Biol* 21 (2020) 501-521.

[42] T. Abe, and S.D. Shapira, Negative Regulation of Cytosolic Sensing of DNA. *Int Rev Cell Mol Biol* 344 (2019) 91-115.

[43] A. Saeed, X. Ruan, H. Guan, J. Su, and S. Ouyang, Regulation of cGAS-Mediated Immune Responses and Immunotherapy. *Adv Sci (Weinh)* 7 (2020) 1902599.

[44] S.L. Ergun, D. Fernandez, T.M. Weiss, and L. Li, STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition. *Cell* 178 (2019) 290-301 e10.

[45] D.L. Burdette, K.M. Monroe, K. Sotelo-Troha, J.S. Iwig, B. Eckert, M. Hyodo, Y. Hayakawa, and R.E. Vance, STING is a direct innate immune sensor of cyclic di-GMP. *Nature* 478 (2011) 515-8.

[46] I.K. Vila, Chamma, H., Steer, A., Taffoni, C., Reinert, L.S., Turtoi, E., Saccas, M., Marines, J., Jin, L., Bonnefont, X., Paludan, S.R., Vlachakis, D., Turtoi, A., Laguette, N., Control of polyunsaturated fatty acids desaturation by Sting regulates inflammatory responses. *bioRxiv* (2020).

- [47] X. Wang, T. Majumdar, P. Kessler, E. Ozhegov, Y. Zhang, S. Chattopadhyay, S. Barik, and G.C. Sen, STING Requires the Adaptor TRIF to Trigger Innate Immune Responses to Microbial Infection. *Cell Host Microbe* 20 (2016) 329-341.
- [48] Y. Li, S.J. James, D.H. Wyllie, C. Wynne, A. Czibula, A. Bukhari, K. Pye, S.M. Bte Mustafah, R. Fajka-Boja, E. Szabo, A. Angyal, Z. Hegedus, L. Kovacs, A.V.S. Hill, C.A. Jefferies, H.L. Wilson, Z. Yongliang, and E. Kiss-Toth, TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. *Proc Natl Acad Sci U S A* 116 (2019) 16479-16488.
- [49] K.L. Jonsson, A. Laustsen, C. Krapp, K.A. Skipper, K. Thavachelvam, D. Hotter, J.H. Egedal, M. Kjolby, P. Mohammadi, T. Prabakaran, L.K. Sorensen, C. Sun, S.B. Jensen, C.K. Holm, R.J. Lebbink, M. Johannsen, M. Nyegaard, J.G. Mikkelsen, F. Kirchhoff, S.R. Paludan, and M.R. Jakobsen, IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP. *Nat Commun* 8 (2017) 14391.
- [50] A. Ablasser, J.L. Schmid-Burgk, I. Hemmerling, G.L. Horvath, T. Schmidt, E. Latz, and V. Hornung, Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. *Nature* 503 (2013) 530-4.
- [51] L. Schadt, C. Sparano, N.A. Schweiger, K. Silina, V. Cecconi, G. Lucchiari, H. Yagita, E. Guggisberg, S. Saba, Z. Nascakova, W. Barchet, and M. van den Broek, Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. *Cell Rep* 29 (2019) 1236-1248 e7.
- [52] G. Pepin, D. De Nardo, C.L. Rootes, T.R. Ullah, S.S. Al-Asmari, K.R. Balka, H.M. Li, K.M. Quinn, F. Moghaddas, S. Chappaz, B.T. Kile, E.F. Morand, S.L. Masters, C.R. Stewart, B.R.G. Williams, and M.P. Gantier, Connexin-Dependent Transfer of cGAMP to Phagocytes Modulates Antiviral Responses. *mBio* 11 (2020).
- [53] J.A. Carozza, V. Böhnert, K.C. Nguyen, G. Skariah, K.E. Shaw, J.A. Brown, M. Rafat, R. von Eyben, E.E. Graves, J.S. Glenn, M. Smith, and L. Li, Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. *Nature Cancer* 1 (2020) 184-196.
- [54] M. Gentili, J. Kowal, M. Tkach, T. Satoh, X. Lahaye, C. Conrad, M. Boyron, B. Lombard, S. Durand, G. Kroemer, D. Loew, M. Dalod, C. Thery, and N. Manel, Transmission of innate immune signaling by packaging of cGAMP in viral particles. *Science* 349 (2015) 1232-6.
- [55] M.A. Ansari, V.V. Singh, S. Dutta, M.V. Veetil, D. Dutta, L. Chikoti, J. Lu, D. Everly, and B. Chandran, Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells. *J Virol* 87 (2013) 8606-23.
- [56] N. Kerur, M.V. Veetil, N. Sharma-Walia, V. Bottero, S. Sadagopan, P. Otageri, and B. Chandran, IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. *Cell Host Microbe* 9 (2011) 363-75.
- [57] S.R. Morrone, T. Wang, L.M. Constantoulakis, R.M. Hooy, M.J. Delannoy, and J. Sohn, Cooperative assembly of IFI16 filaments on dsDNA provides insights into host defense strategy. *Proc Natl Acad Sci U S A* 111 (2014) E62-71.
- [58] D. Dutta, S. Dutta, M.V. Veetil, A. Roy, M.A. Ansari, J. Iqbal, L. Chikoti, B. Kumar, K.E. Johnson, and B. Chandran, BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of

Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-beta Responses. *PLoS Pathog* 11 (2015) e1005030.

[59] J. Her, and S.F. Bunting, How cells ensure correct repair of DNA double-strand breaks. *J Biol Chem* 293 (2018) 10502-10511.

[60] H.H.Y. Chang, N.R. Pannunzio, N. Adachi, and M.R. Lieber, Non-homologous DNA end joining and alternative pathways to double-strand break repair. *Nat Rev Mol Cell Biol* 18 (2017) 495-506.

[61] C. Schwartz, O. Rohr, and C. Wallet, Targeting the DNA-PK complex: Its rationale use in cancer and HIV-1 infection. *Biochem Pharmacol* 160 (2019) 80-91.

[62] X. Zhang, T.W. Brann, M. Zhou, J. Yang, R.M. Oguariri, K.B. Lidie, H. Imamichi, D.W. Huang, R.A. Lempicki, M.W. Baseler, T.D. Veenstra, H.A. Young, H.C. Lane, and T. Imamichi, Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. *J Immunol* 186 (2011) 4541-5.

[63] A.Y. Karpova, M. Trost, J.M. Murray, L.C. Cantley, and P.M. Howley, Interferon regulatory factor-3 is an in vivo target of DNA-PK. *Proc Natl Acad Sci U S A* 99 (2002) 2818-23.

[64] A. Cooper, M. Garcia, C. Petrovas, T. Yamamoto, R.A. Koup, and G.J. Nabel, HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. *Nature* 498 (2013) 376-9.

[65] J.R. Frost, O. Olanubi, S.K. Cheng, A. Soriano, L. Crisostomo, A. Lopez, and P. Pelka, The interaction of adenovirus E1A with the mammalian protein Ku70/XRCC6. *Virology* 500 (2017) 11-21.

[66] C. Bregnard, M. Benkirane, and N. Laguette, DNA damage repair machinery and HIV escape from innate immune sensing. *Front Microbiol* 5 (2014) 176.

[67] M. Morchikh, A. Cribier, R. Raffel, S. Amraoui, J. Cau, D. Severac, E. Dubois, O. Schwartz, Y. Bennasser, and M. Benkirane, HEXIM1 and NEAT1 Long Non-coding RNA Form a Multi-subunit Complex that Regulates DNA-Mediated Innate Immune Response. *Mol Cell* 67 (2017) 387-399 e5.

[68] I.S. Mohiuddin, and M.H. Kang, DNA-PK as an Emerging Therapeutic Target in Cancer. *Front Oncol* 9 (2019) 635.

[69] T. Li, T. Huang, M. Du, X. Chen, F. Du, J. Ren, and Z.J. Chen, Phosphorylation and chromatin tethering prevent cGAS activation during mitosis. *Science* (2021).

[70] S.M. Harding, J.L. Benci, J. Irianto, D.E. Discher, A.J. Minn, and R.A. Greenberg, Mitotic progression following DNA damage enables pattern recognition within micronuclei. *Nature* 548 (2017) 466-470.

[71] T. Kujirai, C. Zierhut, Y. Takizawa, R. Kim, L. Negishi, N. Uruma, S. Hirai, H. Funabiki, and H. Kurumizaka, Structural basis for the inhibition of cGAS by nucleosomes. *Science* 370 (2020) 455-458.

- [72] S. Michalski, C.C. de Oliveira Mann, C.A. Stafford, G. Witte, J. Bartho, K. Lammens, V. Hornung, and K.P. Hopfner, Structural basis for sequestration and autoinhibition of cGAS by chromatin. *Nature* (2020).
- [73] G.R. Pathare, A. Decout, S. Gluck, S. Cavadini, K. Makasheva, R. Hovius, G. Kempf, J. Weiss, Z. Kozicka, B. Guey, P. Melenc, B. Fierz, N.H. Thoma, and A. Ablasser, Structural mechanism of cGAS inhibition by the nucleosome. *Nature* (2020).
- [74] H. Sun, Y. Huang, S. Mei, F. Xu, X. Liu, F. Zhao, L. Yin, D. Zhang, L. Wei, C. Wu, S. Ma, J. Wang, S. Cen, C. Liang, S. Hu, and F. Guo, A Nuclear Export Signal Is Required for cGAS to Sense Cytosolic DNA. *Cell Rep* 34 (2021) 108586.
- [75] E. Mladenov, S. Magin, A. Soni, and G. Iliakis, DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. *Front Oncol* 3 (2013) 113.
- [76] W.D. Wright, S.S. Shah, and W.D. Heyer, Homologous recombination and the repair of DNA double-strand breaks. *J Biol Chem* 293 (2018) 10524-10535.
- [77] H. Liu, H. Zhang, X. Wu, D. Ma, J. Wu, L. Wang, Y. Jiang, Y. Fei, C. Zhu, R. Tan, P. Jungblut, G. Pei, A. Dorhoi, Q. Yan, F. Zhang, R. Zheng, S. Liu, H. Liang, Z. Liu, H. Yang, J. Chen, P. Wang, T. Tang, W. Peng, Z. Hu, Z. Xu, X. Huang, J. Wang, H. Li, Y. Zhou, F. Liu, D. Yan, S.H.E. Kaufmann, C. Chen, Z. Mao, and B. Ge, Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. *Nature* 563 (2018) 131-136.
- [78] H. Jiang, X. Xue, S. Panda, A. Kawale, R.M. Hooy, F. Liang, J. Sohn, P. Sung, and N.O. Gekara, Chromatin-bound cGAS is an inhibitor of DNA repair and hence accelerates genome destabilization and cell death. *EMBO J* 38 (2019) e102718.
- [79] L. Cheradame, Guerrero, I.C., Gaston, J., Schmitt, A., Jung, V., Pouillard, M., Radosevic-Robin, N., Modesti, M., Judde, J., Cairo, S., Goffin, G., STING Promotes Breast Cancer Cell Survival by an Inflammatory-Independent Nuclear Pathway Enhancing the DNA Damage Response. *bioRxiv* (2020).
- [80] M. Zaki-Dizaji, S.M. Akrami, G. Azizi, H. Abolhassani, and A. Aghamohammadi, Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis? *Inflamm Res* 67 (2018) 559-570.
- [81] T. Davis, and D. Kipling, Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome? *Rejuvenation Res* 9 (2006) 402-7.
- [82] M. Gratia, M.P. Rodero, C. Conrad, E. Bou Samra, M. Maurin, G.I. Rice, D. Duffy, P. Revy, F. Petit, R.C. Dale, Y.J. Crow, M. Amor-Gueret, and N. Manel, Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS. *J Exp Med* 216 (2019) 1199-1213.
- [83] F.R. Greten, and S.I. Grivennikov, Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity* 51 (2019) 27-41.
- [84] Z. Dou, K. Ghosh, M.G. Vizioli, J. Zhu, P. Sen, K.J. Wangensteen, J. Simithy, Y. Lan, Y. Lin, Z. Zhou, B.C. Capell, C. Xu, M. Xu, J.E. Kieckhaefer, T. Jiang, M. Shoshkes-Carmel, K. Tanim, G.N. Barber, J.T. Seykora, S.E. Millar, K.H. Kaestner, B.A. Garcia, P.D. Adams, and

S.L. Berger, Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* 550 (2017) 402-406.

[85] S. Gluck, B. Guey, M.F. Gulen, K. Wolter, T.W. Kang, N.A. Schmacke, A. Bridgeman, J. Rehwinkel, L. Zender, and A. Ablasser, Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. *Nat Cell Biol* 19 (2017) 1061-1070.

[86] H. Yang, H. Wang, J. Ren, Q. Chen, and Z.J. Chen, cGAS is essential for cellular senescence. *Proc Natl Acad Sci U S A* 114 (2017) E4612-E4620.

[87] L. Deng, H. Liang, M. Xu, X. Yang, B. Burnette, A. Arina, X.D. Li, H. Mauceri, M. Beckett, T. Darga, X. Huang, T.F. Gajewski, Z.J. Chen, Y.X. Fu, and R.R. Weichselbaum, STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity* 41 (2014) 843-52.

[88] D. Wan, W. Jiang, and J. Hao, Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response. *Front Immunol* 11 (2020) 615.

[89] H. Wang, S. Hu, X. Chen, H. Shi, C. Chen, L. Sun, and Z.J. Chen, cGAS is essential for the antitumor effect of immune checkpoint blockade. *Proc Natl Acad Sci U S A* 114 (2017) 1637-1642.

[90] E. Padovan, G.C. Spagnoli, M. Ferrantini, and M. Heberer, IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. *J Leukoc Biol* 71 (2002) 669-76.

[91] T. Ohkuri, A. Kosaka, K. Ishibashi, T. Kumai, Y. Hirata, K. Ohara, T. Nagato, K. Oikawa, N. Aoki, Y. Harabuchi, E. Celis, and H. Kobayashi, Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. *Cancer Immunol Immunother* 66 (2017) 705-716.

[92] B.C. Burnette, H. Liang, Y. Lee, L. Chlewicki, N.N. Khodarev, R.R. Weichselbaum, Y.X. Fu, and S.L. Auh, The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. *Cancer Res* 71 (2011) 2488-96.

[93] H. Sheng, Y. Huang, Y. Xiao, Z. Zhu, M. Shen, P. Zhou, Z. Guo, J. Wang, H. Wang, W. Dai, W. Zhang, J. Sun, and C. Cao, ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. *J Immunother Cancer* 8 (2020).

[94] L. Wang, L. Yang, C. Wang, W. Zhao, Z. Ju, W. Zhang, J. Shen, Y. Peng, C. An, Y.T. Luu, S. Song, T.A. Yap, J.A. Ajani, G.B. Mills, X. Shen, and G. Peng, Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. *J Clin Invest* 130 (2020) 5951-5966.

[95] J. Ahn, T. Xia, H. Konno, K. Konno, P. Ruiz, and G.N. Barber, Inflammation-driven carcinogenesis is mediated through STING. *Nat Commun* 5 (2014) 5166.

[96] R.M. Chabanon, G. Muirhead, D.B. Krastev, J. Adam, D. Morel, M. Garrido, A. Lamb, C. Henon, N. Dorvault, M. Rouanne, R. Marlow, I. Bajrami, M.L. Cardenosa, A. Konde, B. Besse, A. Ashworth, S.J. Pettitt, S. Haider, A. Marabelle, A.N. Tutt, J.C. Soria, C.J. Lord, and S.

Postel-Vinay, PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. *J Clin Invest* 129 (2019) 1211-1228.

[97] H. Liang, L. Deng, Y. Hou, X. Meng, X. Huang, E. Rao, W. Zheng, H. Mauceri, M. Mack, M. Xu, Y.X. Fu, and R.R. Weichselbaum, Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. *Nat Commun* 8 (2017) 1736.

[98] P. Sharma, S. Hu-Lieskovan, J.A. Wargo, and A. Ribas, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* 168 (2017) 707-723.

[99] Q. Chen, A. Boire, X. Jin, M. Valiente, E.E. Er, A. Lopez-Soto, L. Jacob, R. Patwa, H. Shah, K. Xu, J.R. Cross, and J. Massague, Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. *Nature* 533 (2016) 493-498.

[100] S.F. Bakhom, B. Ngo, A.M. Laughney, J.A. Cavallo, C.J. Murphy, P. Ly, P. Shah, R.K. Sriram, T.B.K. Watkins, N.K. Taunk, M. Duran, C. Pauli, C. Shaw, K. Chadalavada, V.K. Rajasekhar, G. Genovese, S. Venkatesan, N.J. Birkbak, N. McGranahan, M. Lundquist, Q. LaPlant, J.H. Healey, O. Elemento, C.H. Chung, N.Y. Lee, M. Imielenski, G. Nanjangud, D. Pe'er, D.W. Cleveland, S.N. Powell, J. Lammerding, C. Swanton, and L.C. Cantley, Chromosomal instability drives metastasis through a cytosolic DNA response. *Nature* 553 (2018) 467-472.

[101] T. Sen, B.L. Rodriguez, L. Chen, C.M.D. Corte, N. Morikawa, J. Fujimoto, S. Cristea, T. Nguyen, L. Diao, L. Li, Y. Fan, Y. Yang, J. Wang, B.S. Glisson, Wistuba, II, J. Sage, J.V. Heymach, D.L. Gibbons, and L.A. Byers, Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. *Cancer Discov* 9 (2019) 646-661.

[102] M.T. Dillon, K.F. Bergerhoff, M. Pedersen, H. Whittock, E. Crespo-Rodriguez, E.C. Patin, A. Pearson, H.G. Smith, J.T.E. Paget, R.R. Patel, S. Foo, G. Bozhanova, C. Ragulan, E. Fontana, K. Desai, A.C. Wilkins, A. Sadanandam, A. Melcher, M. McLaughlin, and K.J. Harrington, ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. *Clin Cancer Res* 25 (2019) 3392-3403.

[103] P.M. Schoonen, Y.P. Kok, E. Wierenga, B. Bakker, F. Fojier, D.C.J. Spierings, and M. van Vugt, Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. *Mol Oncol* 13 (2019) 2422-2440.

[104] C. Kim, X.D. Wang, and Y. Yu, PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. *Elife* 9 (2020).

[105] T. Xia, H. Konno, J. Ahn, and G.N. Barber, Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. *Cell Rep* 14 (2016) 282-97.

[106] S. Song, P. Peng, Z. Tang, J. Zhao, W. Wu, H. Li, M. Shao, L. Li, C. Yang, F. Duan, M. Zhang, J. Zhang, H. Wu, C. Li, X. Wang, H. Wang, Y. Ruan, and J. Gu, Decreased expression of STING predicts poor prognosis in patients with gastric cancer. *Sci Rep* 7 (2017) 39858.

[107] B.S. Parker, J. Rautela, and P.J. Hertzog, Antitumour actions of interferons: implications for cancer therapy. *Nat Rev Cancer* 16 (2016) 131-44.

- [108] L. Xia, S. Tan, Y. Zhou, J. Lin, H. Wang, L. Oyang, Y. Tian, L. Liu, M. Su, H. Wang, D. Cao, and Q. Liao, Role of the NFkappaB-signaling pathway in cancer. *Onco Targets Ther* 11 (2018) 2063-2073.
- [109] D.C. Chonov, M.M.K. Ignatova, J.R. Ananiev, and M.V. Gulubova, IL-6 Activities in the Tumour Microenvironment. Part 1. *Open Access Maced J Med Sci* 7 (2019) 2391-2398.
- [110] J.A. Aglipay, S.W. Lee, S. Okada, N. Fujiuchi, T. Ohtsuka, J.C. Kwak, Y. Wang, R.W. Johnstone, C. Deng, J. Qin, and T. Ouchi, A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. *Oncogene* 22 (2003) 8931-8.
- [111] H. Tawara, N. Fujiuchi, J. Sironi, S. Martin, J. Aglipay, M. Ouchi, M. Taga, P.L. Chen, and T. Ouchi, Loss of p53-regulatory protein IFI16 induces NBS1 leading to activation of p53-mediated checkpoint by phosphorylation of p53 SER37. *Front Biosci* 13 (2008) 240-8.
- [112] N. Fujiuchi, J.A. Aglipay, T. Ohtsuka, N. Maehara, F. Sahin, G.H. Su, S.W. Lee, and T. Ouchi, Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. *J Biol Chem* 279 (2004) 20339-44.
- [113] J.T. Crowl, E.E. Gray, K. Pestal, H.E. Volkman, and D.B. Stetson, Intracellular Nucleic Acid Detection in Autoimmunity. *Annu Rev Immunol* 35 (2017) 313-336.
- [114] X.D. Li, J. Wu, D. Gao, H. Wang, L. Sun, and Z.J. Chen, Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. *Science* 341 (2013) 1390-4.
- [115] C.C. de Oliveira Mann, M.H. Orzalli, D.S. King, J.C. Kagan, A.S.Y. Lee, and P.J. Kranzusch, Modular Architecture of the STING C-Terminal Tail Allows Interferon and NF-kappaB Signaling Adaptation. *Cell Rep* 27 (2019) 1165-1175 e5.
- [116] I.K. Vila, M. Fretaud, D. Vlachakis, N. Laguette, and C. Langevin, Animal Models for the Study of Nucleic Acid Immunity: Novel Tools and New Perspectives. *J Mol Biol* 432 (2020) 5529-5543.
- [117] A. Murira, and A. Lamarre, Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. *Front Immunol* 7 (2016) 609.
- [118] D.M. Schwartz, Y. Kanno, A. Villarino, M. Ward, M. Gadina, and J.J. O'Shea, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. *Nat Rev Drug Discov* 17 (2017) 78.
- [119] M. Motwani, S. Pesiridis, and K.A. Fitzgerald, DNA sensing by the cGAS-STING pathway in health and disease. *Nat Rev Genet* 20 (2019) 657-674.